Home  |  Contact

Cellosaurus ACSuR (CVCL_XI64)

[Text version]
Cell line name ACSuR
Accession CVCL_XI64
Resource Identification Initiative To cite this cell line use: ACSuR (RRID:CVCL_XI64)
Comments Group: Patented cell line.
Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014238.
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:38940; Sunitinib.
Misspelling: ACSu; CCRID=4201PAT-CCTCC00548.
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Mutation; HGNC; 7773; NF2; Simple; p.Arg57Ter (c.169C>T); ClinVar=VCV000003285; Zygosity=Homozygous (from parent cell line).
Disease Papillary renal cell carcinoma (NCIt: C6975)
Papillary renal cell carcinoma (ORDO: Orphanet_319298)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1067 (ACHN)
Sex of cell Male
Age at sampling 22Y
Category Cancer cell line
Publications

Patent=CN104988122B
Qu L., Wang L.-H., Liu B., Chen C., Wu Z.-J., Zhang W.
Renal cancer sunitinib drug-resistant cell system and establishment method thereof.
Patent number CN104988122B, 21-Sep-2018

Cross-references
Cell line databases/resources cancercelllines; CVCL_XI64
CCRID; 4201PAT-CCTCC00548
CCRID; 4201PAT-CCTCC00565
Encyclopedic resources Wikidata; Q93313455
Entry history
Entry creation19-Dec-2019
Last entry update05-Oct-2023
Version number8